Testing whether a gene variant affects methotrexate response in psoriatic arthritis
Tests methotrexate against placebo in adults with psoriatic arthritis, linked to a CARD14 gene variant.
Plain-language title generated from the registry record
Registry title: Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient
Key facts
- Where
- Qina, EgyptSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Source: NCT06870500, who can take part
Where in Egypt
- Qina University hospital, South Valley University HospitalQina, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- South Valley University
- Trial code
- NCT06870500
- Record updated
- 11 March 2025
- Original description
Psoriasis is a chronic, immune-mediated, multisystemic, inflammatory disease caused by the interaction of multiple susceptibility genes and environmental factors that affects 1-3% of the population worldwide .Psoriasis also is a chronic inflammatory skin disease characterized by scaly indurated erythema.Read full original descriptionShow less
Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient and Its Relation With Response to Methotrexate
Psoriasis is a chronic, immune-mediated, multisystemic, inflammatory disease caused by the interaction of multiple susceptibility genes and environmental factors that affects 1-3% of the population worldwide .Psoriasis also is a chronic inflammatory skin disease characterized by scaly indurated erythema.
Psoriatic arthritis (PsA) is an autoimmune and chronic musculoskeletal disorder that is associated with psoriasis of the skin . Its presentation can vary from subtle manifestations to highly destructive forms. Joint pain, stiffness and swelling are the most common symptoms.
Inclusion: Patients aged 18 years and above; Patients having psoriasis diagnosed clinically and who have a severity grade of moderate to severe, defined as a Psoriasis Area and Severity Index (PASI) score from 5- 10 % of body surface area, and involvement of greater than 10% of the body surface area (BSA) with or without psoriatic arthritis.
Exclusion: Patients currently undergoing immunosuppressive or systemic therapies; Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus); Patients with known genetic disorders affect immune system function; Patients with liver or kidney impairment; Patients with allergy or contraindication to methotrexate; Patients with active or uncontrolled infections, including chronic infections like tuberculosis; Pregnancy and lactation.